LEADER 00758nam a2200229 i 4500
001 991002921899707536
005 20020509105048.0
008 000220s1964    it            ||| | ita  
035   $ab11081004-39ule_inst
035   $aPARLA171568$9ExL
040   $aDip.to Filosofia$bita
082 0 $a195
100 1 $aArata, Carlo$0159057
245 10$aEvidenza ed essere /$cCarlo Arata
260   $aMilano :$bMarzorati,$c1964
300   $a241 p. ;$c22 cm
907   $a.b11081004$b21-09-06$c28-06-02
912   $a991002921899707536
945   $aLE005IF XXIII E 31$g1$i2005000099731$lle005$o-$pE0.00$q-$rl$s-  $t0$u0$v0$w0$x0$y.i11211283$z28-06-02
996   $aEvidenza ed essere$9860490
997   $aUNISALENTO
998   $ale005$b01-01-00$cm$da  $e-$fita$git $h0$i1

LEADER 01661oam  2200433Ia 450 
001 9910699067803321
005 20120802144757.0
035   $a(CKB)5470000002399206
035   $a(OCoLC)430352118
035   $a(EXLCZ)995470000002399206
100   $a20090813d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAspirin for the primary prevention of cardiovascular events$b[electronic resource] $ean update of the evidence /$fprepared by Tracy Wolff, Therese Miller, and Stephen Ko
210  1$aRockville, MD :$cAgency for Healthcare Research and Quality, U.S. Preventive Services Task Force,$d[2009]
215   $a1 online resource
225 1 $aAHRQ publication ;$vno. 09-05129-EF-4
300   $aTitle from caption title screen (AHRQ, viewed July 9, 2009).
300   $a"Date: March 2009."
517   $aAspirin for the primary prevention of cardiovascular events 
606   $aAspirin$xTherapeutic use
606   $aCardiovascular system$xDiseases$xPrevention
615  0$aAspirin$xTherapeutic use.
615  0$aCardiovascular system$xDiseases$xPrevention.
700   $aWolff$b Tracy$g(Tracy A.)$01379729
701   $aMiller$b Therese$01413493
701   $aKo$b Stephen$01413494
712 02$aUnited States.$bAgency for Healthcare Research and Quality.
712 02$aU.S. Preventive Services Task Force.
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910699067803321
996   $aAspirin for the primary prevention of cardiovascular events$93509993
997   $aUNINA